BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
Nomura downgrades IPCA Laboratories to neutral
IPCA progress on the regulatory front after the import alert has been slower than expectations. The delay in pick-up in US sales of HCQS (used in treatment of rheumatoid arthritis) and the Global Fund business along with one-time FDA resolution related costs have adversely impacted FY16 estimates.